aTyr Pharma, Inc.
ATYR
$3.28
$0.185.81%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -64.02M | -63.82M | -57.90M | -53.93M | -50.39M |
| Total Depreciation and Amortization | 1.54M | 1.95M | 2.55M | 2.76M | 2.74M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 282.00K | -162.00K | -618.00K | -851.00K | -585.00K |
| Change in Net Operating Assets | -6.92M | -5.02M | -7.49M | -2.99M | 15.01M |
| Cash from Operations | -69.12M | -67.05M | -63.45M | -55.01M | -33.22M |
| Capital Expenditure | -65.00K | -57.00K | -599.00K | -2.99M | -4.22M |
| Sale of Property, Plant, and Equipment | 7.00K | 0.00 | 0.00 | 15.00K | 15.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.29M | 41.19M | 28.17M | 19.66M | -15.93M |
| Cash from Investing | 17.23M | 41.14M | 27.57M | 16.69M | -20.13M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -497.00K | -484.00K | -467.00K | -449.00K | -394.00K |
| Issuance of Common Stock | 40.36M | 27.54M | 30.31M | 24.91M | 66.62M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 39.86M | 27.06M | 29.85M | 24.46M | 66.23M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12.02M | 1.15M | -6.03M | -13.86M | 12.88M |